Member Info for Agenda101

26 March 2026

Avacta continues to progress the Phase 1b expansion cohorts of faridoxorubicin (AVA6000). These cohorts have nearly completed enrollment in three indications: salivary gland cancer (SGC), triple negative breast cancer (TNBC) and soft tissue sarcoma (STS). The Company will release additional data from the Phase 1a and Phase 1b cohorts in 1H 2026, updating the efficacy in the lead indication of SGC as well as the other indications and the cardiac safety data that led to the removal of the lifetime maximum dosing of faridoxorubicin. The Board expects these data collectively will solidify the view of the value of faridoxorubicin.

Expecting something along this at some stage today B2HS2L

H1 2026. Not H2..

Mañana!🤗

Tomorrow?

The key takeaway is that the FDA has agreed Avacta may only need a single pivotal trial for full approval of AVA6000 in salivary gland cancer, with progression free survival as the sole primary endpoint. That potentially removes the need for multiple registrational studies, reducing development time, cost and regulatory risk while providing a much clearer path to market.

Why is everyone so infatuated with Touk? It’s years now and still you cannot green bin him.. why is it everytime I come on this board it’s arguments regarding Touk or wydy..

Your all as bad as them..

For years it’s been the 3 amigos or Touk and none of you can let it be.. you all need your heads examining.

I didn’t realise people are that Stupid, but I’m proven wrong! Idiots..

The presentation paired with the looming mid-year data timelines for the TNBC patient cohort, is entirely about showing the medical community that this targeted delivery mechanism safely unlocks the full power of a classic chemotherapy drug

Financially and operationally, tomorrow represents a major structural focal point for the company.The Agreement: Under the terms of Avacta's amended convertible bond agreements, June 30, 2026 is the final backstop date linked to the publication of the Phase 1b trial data readouts for AVA6000 in TNBC.

GLA

It must be renamed as : WYN Group Share Chat?

Everytime I take a peek at the board.. The top header is always about Wyn(I’ve blocked him yrs ago)…

I think I’ll unblock..

He is definitely the King Of This Chat Group and he’s been king of this board for years…..

Something to be proud of Wyn, keep up the good work.. I’d certainly pay this guy to disrupt! He’s not that stupid tbh… he’s had all of you furiously frustrated at times…

Keep up the good work and what your paid to do!👍

what more needs to be said. your all as bad as each other.. it’s absolutely shocking..**** board with no content!

We wait…….

Meaning:

“The measured biological signals are showing positive signs that the drug is working as intended”.

Will we see a surge in ISA top ups today?👀

“ leading oncologists are currently reviewing the emerging data and have noted that the results appear to be exceptional. Their early assessments further reinforce the strength and potential significance of these findings, lending additional credibility and optimism as the data continues to be evaluated in greater depth.

Https://www.londonstockexchange.com/news-article/AVCT/first-patient-treated-in-phase-1-trial-of-ava6103/17526769

Despite significant interest in AVA6103, the Company's strategy remains to retain all rights to AVA6103 at least until the Company has sight of the initial results from the Phase 1a trial.

Thanks to Stonks

https://x.com/jstonker/status/2031270617169703402?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

Https://x.com/jenkoool/status/2029251745612763522?s=46&t=duWTVR3YhEB6IsWdJtkMpQ

Or here

https://avacta.com/events-presentations/46th-annual-td-cowen-health-care-conference-in-boston/